Amgen Seeks Expanded Approval of Kyprolis to Once-weekly Regimen for Relapsed Myeloma
Amgen is seeking to expand the approval of…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA Grants Priority Review to Empliciti Combo Therapy for Relapsed or Refractory Myeloma
The U.S. Food and Drug Administration granted priority…
BL-8040 Speeds Collection of Stem Cells for Transplant in Myeloma Patients, Phase 3 Data Suggest
Adding BioLineRx‘s BL-8040 to standard treatment greatly…
Surface Oncology’s SRF231 Granted Orphan Drug Status for Treatment of Multiple Myeloma
SRF231, an experimental anti-CD47 immunotherapy candidate developed by…
Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma
The U.S. Food and Drug Administration has granted orphan…
CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients
Expanded use of Darzalex (daratumumab) in combination with standard therapy…
